当前位置: X-MOL 学术Diabetes Obes. Metab. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Efficacy and safety of once-monthly efpeglenatide in patients with type 2 diabetes: Results of a phase 2 placebo-controlled, 16-week randomized dose-finding study.
Diabetes, Obesity and Metabolism ( IF 5.4 ) Pub Date : 2020-03-03 , DOI: 10.1111/dom.14020
Stefano Del Prato 1 , Jahoon Kang 2 , Michael E Trautmann 3 , John Stewart 4 , Christopher H Sorli 5 , Michael Derwahl 6 , Alfonso Soto 7 , Kun-Ho Yoon 8
Affiliation  

To determine the optimal dose(s) of once‐monthly administration of efpeglenatide, a long‐acting glucagon‐like peptide‐1 receptor agonist (GLP‐1RA), in patients with type 2 diabetes (T2D) inadequately controlled on metformin.

中文翻译:

每月一次efpeglenatide在2型糖尿病患者中的疗效和安全性:2期安慰剂对照,16周随机剂量研究的结果。

在二甲双胍控制不充分的2型糖尿病(T2D)患者中,为确定每月一次长效胰高血糖素样肽-1受体激动剂(GLP -1RA)每月一次服用efpeglenatide的最佳剂量。
更新日期:2020-03-03
down
wechat
bug